Addressing racial differences in the management of atrial fibrillation: Focus on black patients

Hakeem Ayinde1, Favour Markson2, Ugonna Kevin Ogbenna3

  • 1Cardiology Associates of Fredericksburg, Fredericksburg, VA, USA.

Insights

Black patients experience worse outcomes with atrial fibrillation (AF), despite lower prevalence. Addressing disparities in AF care is crucial for improving health equity and patient results.

Area of Science:

  • Cardiology
  • Public Health
  • Health Disparities

Background:

  • Atrial fibrillation (AF) is a prevalent cardiac arrhythmia impacting millions, significantly reducing quality of life and increasing risks of stroke, heart failure, and mortality.
  • While Black patients exhibit lower AF prevalence compared to White patients, they disproportionately face severe outcomes and complications from the condition.

Purpose of the Study:

  • To highlight the significant disease burden and existing management gaps in Black patients with atrial fibrillation.
  • To emphasize the need for stakeholders to recognize and address the inequities in AF care experienced by the Black population.

Main Methods:

  • This study is a review of existing literature and epidemiological data on atrial fibrillation prevalence, outcomes, and treatment disparities.
  • Analysis focuses on comparing AF-related health outcomes and healthcare access between Black and White patient populations in the United States.

Main Results:

  • Black patients with AF demonstrate a higher likelihood of experiencing adverse outcomes, including increased mortality and complications, compared to White patients.
  • Identified management gaps include delayed diagnosis, suboptimal risk factor control, and limited access to specialized cardiovascular care for Black individuals with AF.

Conclusions:

  • Urgent attention is required to address the disproportionate burden of atrial fibrillation and associated negative outcomes among Black patients.
  • Implementing targeted interventions, such as aggressive risk factor management, timely specialist referrals, and enhanced healthcare access, can help mitigate these disparities and improve patient outcomes.

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
21
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
970
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
844
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174